# SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

> **NCT05375084** · PHASE1 · TERMINATED · sponsor: **Navire Pharma Inc., a BridgeBio company** · enrollment: 21 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Solid Tumor

## Interventions

- **DRUG:** BBP-398 with nivolumab

## Key facts

- **NCT ID:** NCT05375084
- **Lead sponsor:** Navire Pharma Inc., a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-20
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-07-15
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375084, "SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05375084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*